🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💫🌟🔬 Unraveling the Genetic Landscape of Testicular Germ Cell Tumors (TGCT)! 🧬🌟💫 ❗️Largest whole-exome meta-analysis in TGCT to date sheds light on genetic predisposition in 1,435 cases vs. 18,284 controls. #ZeidKuzbari Charlie Rowlands #IsaacWade #AliceGarrett Chey Loveday

📺 In part 1 of a new roundtable moderated by Alan H Bryce, expert panelists discuss advances in biomarker testing, treatment intensification, and best practices for integrating next-generation sequencing into clinical #prostatecancer care: buff.ly/6TYvvuL 👉 The panel

So grateful to the brave patients and their families that made this clinical trial possible, an entirely new way to restore sensitivity to immunotherapy using plasma exchange. Mayo Clinic Mayo Clinic Comprehensive Cancer Center Fabrice Lucien, PhD Nat Comm rdcu.be/edrKN

Thrilled to celebrate my incredible fellows matching into Internal Medicine Residency programs! 🎉 Your hard work, dedication, and resilience have been truly inspiring. It’s bittersweet seeing you move to the next chapter—you’ve become family. Super proud and excited to see all

⭐️Tour de force CAR-T cell for renal cell cancer presentation by Dr. Tanya Dorff City of Hope . These studies are currently open for clinical trial enrollment. Preliminary studies look very promising. Tanya Dorff #MatosGU25 Petros Grivas Sumanta K. Pal, MD, FASCO Yousef Zakharia Hans Hammers

Thanks for the session Oncology Brothers. It was a pleasure to work with you.

Treatment Algorithm: This is the algorithm we’ve used during our discussion w/ Alan H Bryce on #ProstateCancer. #OncTwitter #MedTwitter CancerNetwork®

A few things to keep in mind 1. 👇recent updates in prostate cancer staging 2. Solitary rib Mets on PET-PSMA are often benign 3. Response of PARPi based off HRR mutation (slide by Alan H Bryce) 4. Survival by subgroups (slide from Alan H Bryce) x.com/nicholaszaorsk…

I have to challenge this. We don’t yet have clear trial data to establish platinum efficacy in HRR mutated mCRPC. However platinum is unequivocally more toxic than PARPi, especially with regards to neuropathy. I have had multiple patients on PARPi for >24 months. No way you

Best talk I have been to all year was right here at City of Hope at our GU retreat (organized by Alex Chehrazi-Raffle, MD). Yun Rose Li City of Hope - Department of Radiation Oncology just delivered a tour de force highlighting her work in #prostatecancer w Tanya Dorff et al focused on fasting interventions & other metabolic

Terrific talks from William Dale, MD, PhD, FASCO, Walter Stadler, Yun Rose Li & #MahaHussainMD in a terrific City of Hope symposium hosted by Alex Chehrazi-Raffle, MD.

#TRITON3 final overall survival results for rucaparib in BRCA-mutated #ProstateCancer. Alan H Bryce City of Hope joins Alicia Morgans, MD, MPH Dana-Farber to discuss the phase III study which evaluated rucaparib against physician's choice therapy (predominantly docetaxel) in

Congratulations to Cathy Marshall on her two papers (in the same week!) exploring CH in solid tumors. This is an important and emerging field. Cathy Handy Marshall, MD MPH Tempus academic.oup.com/oncolo/article… mdpi-res.com/d_attachment/c…

#AUA25 Ana Moser Wayne State University School of Medicine tackled the question: Who still needs a lymph node dissection with a negative PSMA-PET? Key findings included: 🔹 n=359 PSMA-PET before RP+PLND 📉 21 cN1: 15 pN0, 6 pN1; 28 cN0 were pN1 🎯 NPV: 91%, PPV: 29% ⚠️ cN0/pN1: More NCCN high-risk (65%) +

🚨 New ASCO Guideline on #mCRPC just published! Glad to co-author recs on sequencing, #PARP inhibitors, #genomics, chemo & radiopharmaceuticals Grateful to expert panel R. Bryan Rumble Irbaz Riaz MD,MS,MBI,PhD #RahulParikh Alan H Bryce Journal of Clinical Oncology OncoAlert OncLive.com 🔗ascopubs.org/doi/10.1200/JC…

Had so much fun (see interview bit.ly/4j2BScj ) at the inaugural GU Early Thought Leaders 2025 Conference with Zach Klaassen where we met many future #GUOncology leaders! Prostate Cancer Foundation UroToday.com with outstanding faculty Elizabeth Plimack MD Sumanta K. Pal, MD, FASCO Arjun Balar MD Alan H Bryce Trinity J. Bivalacqua

Join City of Hope and Marcel van den Brink for an evening of connection and conversation during #ASCO25! Submit your R.S.V.P. to [email protected].

Thank you for communicating the data Dr. Patrick Hwu

Great data. I’m particularly impressed by the benefit seen in with Talazoparib + Enzalutamide CDK12 mutant mCRPC. PFS and OS benefit. I think this is still an underappreciated benefit.

IMO the most important message here is the importance of paying attention to CV dz for men with advanced PC. Our must do checklist for men with advanced PC should include: 1) Germline + somatic NGS 2) Manage CV health 3) Manage Bone health